Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
Active‐control crossover study randomizing 32 healthy volunteers to receive one of two dose levels, 325 mg or 650 mg, of either PL‐ASA or immediate release aspirin within a two week washout period between treatments. The primary objectives are to assess PK and PD bioequivalence and safety over a twenty four hour period for PL‐ASA and immediate release aspirin at 325 mg and 650 mg dose strengths.
Epistemonikos ID: e4fd72c6249e33a526edd0dc5d5594ece04405e5
First added on: May 22, 2024